Alternatives to Padcev If You Can't Fill Your Prescription

Padcev (enfortumab vedotin-ejfv) has become a cornerstone of urothelial cancer treatment since its FDA approval in 2019, and the Padcev plus pembrolizumab combination is now considered first-line standard of care for most patients with locally advanced or metastatic urothelial cancer. But what happens if insurance denies coverage, you experience intolerable side effects, or you're unable to access a suitable infusion center?

The good news: there are several other FDA-approved treatment options for urothelial cancer. Which alternative is right for you depends on your prior treatment history, tumor biomarker profile, overall health, and insurance coverage. Always discuss any changes with your oncologist before switching treatments.

Why Patients Sometimes Need Alternatives to Padcev

Patients may need to explore alternatives for several reasons:

Side effects: Padcev carries a boxed warning for severe skin reactions (SJS/TEN) and can cause peripheral neuropathy, hyperglycemia, and eye problems that lead some patients to discontinue

Pre-existing conditions: Patients with poorly controlled diabetes, severe pre-existing neuropathy, or active autoimmune disorders may not be good candidates

Insurance denial: Prior authorization may be denied, and appeals can take time

Disease progression: If cancer progresses on Padcev, alternative agents are needed

Alternative 1: Erdafitinib (Balversa) — For FGFR-Mutated Tumors

Erdafitinib (Balversa) is an oral pan-FGFR inhibitor approved for locally advanced or metastatic urothelial cancer with susceptible FGFR2 or FGFR3 gene alterations. In the phase 3 THOR trial, erdafitinib showed an overall survival benefit compared to chemotherapy in patients with FGFR-positive tumors (HR 0.64).

Key advantage: It's an oral pill taken at home, which may be preferable for patients who struggle to get to infusion centers. Response rates are approximately 40% in FGFR-positive patients. A biomarker test (next-generation sequencing) is required to confirm FGFR2/3 mutations.

Alternative 2: Pembrolizumab (Keytruda) — PD-1 Checkpoint Inhibitor

Pembrolizumab (Keytruda) is an IV immunotherapy agent approved as second-line therapy for urothelial cancer and in cisplatin-ineligible patients in the first-line setting. In the KEYNOTE-045 trial, pembrolizumab extended median OS to 10.3 months vs 7.4 months with chemotherapy. While less effective than the Padcev+pembrolizumab combination, pembrolizumab monotherapy is an established, well-tolerated option with manageable side effects for many patients.

Alternative 3: Nivolumab (Opdivo) — PD-1 Inhibitor Approved in Combination

Nivolumab (Opdivo) was approved in March 2024 in combination with gemcitabine and cisplatin for unresectable or metastatic urothelial carcinoma. The CheckMate 901 trial showed improved overall survival vs chemotherapy alone. Nivolumab + gemcitabine/cisplatin is a viable first-line option for cisplatin-eligible patients who are not candidates for Padcev-based regimens.

39,483+ patients found their medications in stock

39K+

Find Padcev In Stock Today →

Alternative 4: Platinum-Based Chemotherapy (Gemcitabine + Cisplatin or Carboplatin)

Gemcitabine combined with cisplatin (for cisplatin-eligible patients) or carboplatin (for cisplatin-ineligible) remains a standard treatment for locally advanced or metastatic urothelial cancer. These regimens are widely available, generally covered by insurance, and administered at most infusion centers. They are often used when newer agents are not accessible or have been contraindicated.

Alternative 5: Fam-Trastuzumab Deruxtecan (Enhertu) — For HER2-Positive Disease

For patients whose tumors are HER2 3+ (IHC), fam-trastuzumab deruxtecan-nxki (Enhertu) is listed in NCCN guidelines as a recommended regimen. It is another antibody-drug conjugate that targets HER2 rather than Nectin-4. HER2 testing via IHC is required to determine eligibility.

Skip the calls, skip the stress.

Find Padcev In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Clinical Trials as an Alternative

Urothelial cancer is a rapidly evolving treatment space with numerous active clinical trials. If standard therapies are not accessible or have failed, enrolling in a clinical trial may provide access to cutting-edge treatments — sometimes at no cost. Search clinicaltrials.gov for urothelial or bladder cancer trials in your area.

How to Discuss Alternatives With Your Doctor

When discussing alternatives with your oncologist, bring:

Documentation of why Padcev was not accessible (insurance denial letter, side effect records)

Your most recent biomarker testing results (FGFR2/3, HER2, PD-L1)

A list of your current medications to screen for interactions

Questions about clinical trial eligibility

If your primary issue is locating a facility that can administer Padcev, medfinder can help find infusion centers near you before you switch to an alternative therapy.

Also read: How to Save Money on Padcev in 2026: Coupons, Discounts, and Patient Assistance.